IVD Reagents Market by Type, technology, Application, Test Type, End User & Region - Global Forecast to 2029

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 MARKET RECONCILIATION

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key industry insights
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.2.1.3 Approach 3: Primary interviews
    • 2.2.1.4 Growth forecast
    • 2.2.1.5 CAGR projections
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 RESEARCH ASSUMPTIONS
  • 2.4.1 STUDY-RELATED ASSUMPTIONS
  • 2.4.2 PARAMETRIC ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
• 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 IVD REAGENTS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: IVD REAGENTS MARKET, BY COUNTRY
• 4.3 NORTH AMERICA: IVD REAGENTS MARKET, BY TEST TYPE AND COUNTRY
• 4.4 IVD REAGENTS MARKET, BY COUNTRY

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing geriatric population
    • 5.2.1.2 Gradual shift toward point-of-care testing and automated analyzers
    • 5.2.1.3 Rise in early diagnosis and personalized medicine
    • 5.2.1.4 Increasing adoption of third-party quality controls
    • 5.2.1.5 Growing biotechnology and biopharmaceutical industries
    • 5.2.1.6 Increasing funding for R&D activities
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Unfavorable reimbursement scenario
    • 5.2.2.2 Stringent regulatory requirements
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing development of biomarkers
    • 5.2.3.2 Rising significance of companion diagnostics
    • 5.2.3.3 Market growth opportunities in emerging economies
    • 5.2.3.4 Growing trend of digitalization
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Operational challenges in clinical process
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION
  • 5.4.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY REGION
  • 5.4.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
  • 5.9.2 ADJACENT TECHNOLOGIES
    • 5.9.2.1 Multiplexed point-of-care testing
    • 5.9.2.2 Nucleic acid lateral flow immunoassay
    • 5.9.2.3 DNA-based detection
    • 5.9.2.4 Immunodiagnostics
    • 5.9.2.5 Dual path technology
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA
  • 5.11.2 EXPORT DATA
• 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT OF NEW ENTRANTS
  • 5.13.2 THREAT OF SUBSTITUTES
  • 5.13.3 BARGAINING POWER OF SUPPLIERS
  • 5.13.4 BARGAINING POWER OF BUYERS
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 REGULATORY ANALYSIS
  • 5.14.1 REGULATORY LANDSCAPE
    • 5.14.1.1 North America
      • 5.14.1.1.1 US
      • 5.14.1.1.2 Canada
    • 5.14.1.2 Europe
    • 5.14.1.3 Asia Pacific
      • 5.14.1.3.1 China
      • 5.14.1.3.2 Japan
      • 5.14.1.3.3 India
    • 5.14.1.4 Latin America
      • 5.14.1.4.1 Brazil
    • 5.14.1.5 Middle East
  • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.14.2.1 North America
    • 5.14.2.2 Europe
    • 5.14.2.3 Asia Pacific
    • 5.14.2.4 Latin America
    • 5.14.2.5 Middle East & Africa
    • 5.14.2.6 GCC Countries
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 BUYING CRITERIA
• 5.16 IMPACT OF AI/GENERATIVE AI ON IVD REAGENTS MARKET
  • 5.16.1 INTRODUCTION
  • 5.16.2 MARKET POTENTIAL FOR IVD REAGENTS
  • 5.16.3 AI USE CASES
  • 5.16.4 KEY COMPANIES IMPLEMENTING AI
  • 5.16.5 FUTURE OF GENERATIVE AI ON IVD REAGENTS

6 IVD REAGENTS MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 ANTIBODIES
  • 6.2.1 MONOCLONAL ANTIBODIES
    • 6.2.1.1 Increasing incidence of cancer to stimulate growth
  • 6.2.2 POLYCLONAL ANTIBODIES
    • 6.2.2.1 Rising prevalence of infectious diseases and autoimmune disorders to support growth
• 6.3 ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES
  • 6.3.1 INCREASING FOCUS ON ADVANCED PRECISION MEDICINE TO ENCOURAGE GROWTH
• 6.4 OLIGONUCLEOTIDES
  • 6.4.1 GROWING INCLINATION TOWARD MOLECULAR DIAGNOSTICS TO DRIVE MARKET
• 6.5 NUCLEIC ACID PROBES
  • 6.5.1 NEED FOR EARLY DISEASE DETECTION AND MONITORING LOW-ABUNDANCE BIOMARKERS TO AID GROWTH
• 6.6 OTHER IVD REAGENTS

7 IVD REAGENTS MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 IMMUNOASSAYS
  • 7.2.1 RISING TREND OF AUTOMATION TO PROMOTE GROWTH
• 7.3 CLINICAL CHEMISTRY
  • 7.3.1 RISING PREVALENCE OF DIABETES TO BOOST SEGMENT
• 7.4 MOLECULAR DIAGNOSTICS
  • 7.4.1 GROWING DEMAND FOR BLOOD SCREENING AND POINT-OF-CARE TESTING TO FUEL MARKET
• 7.5 HEMATOLOGY
  • 7.5.1 INCREASING FOCUS ON STEM CELL RESEARCH TO SPEED UP GROWTH
• 7.6 MICROBIOLOGY
  • 7.6.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET
• 7.7 COAGULATION & HEMOSTASIS
  • 7.7.1 GROWING USE OF ANTICOAGULATION THERAPY TO PROPEL MARKET
• 7.8 URINALYSIS
  • 7.8.1 RISING PREVALENCE OF KIDNEY DISEASES TO SUPPORT MARKET GROWTH
• 7.9 CHROMATOGRAPHY & MASS SPECTROMETRY
  • 7.9.1 INCREASING APPLICATIONS IN DISEASE SCREENING, FORENSIC ANALYSIS, AND DRUG THERAPY TO BOOST MARKET
• 7.10 IMMUNOHISTOCHEMISTRY
  • 7.10.1 GROWING NUMBER OF LABORATORY TESTS FOR CANCER DIAGNOSIS TO DRIVE MARKET

8 IVD REAGENTS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 INFECTIOUS DISEASES
  • 8.2.1 INCREASING PRODUCT LAUNCHES AND APPROVALS TO BOOST MARKET
• 8.3 ONCOLOGICAL APPLICATIONS
  • 8.3.1 GROWING EMPHASIS ON EARLY DIAGNOSIS AND QUALITY TREATMENT TO FUEL MARKET
• 8.4 ENDOCRINOLOGICAL APPLICATIONS
  • 8.4.1 RISING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO SUSTAIN GROWTH
• 8.5 CARDIOLOGICAL APPLICATIONS
  • 8.5.1 CHANGING LIFESTYLES IN DEVELOPED AND DEVELOPING COUNTRIES TO PROPEL MARKET
• 8.6 BLOOD SCREENING
  • 8.6.1 RISING ADOPTION OF AUTOMATED DIAGNOSTIC INSTRUMENTS TO FACILITATE GROWTH
• 8.7 GENETIC TESTING
  • 8.7.1 INCREASING ADOPTION OF GENETIC TESTING TO DIAGNOSE RARE AND FATAL DISEASES TO SUSTAIN GROWTH
• 8.8 AUTOIMMUNE DISEASES
  • 8.8.1 GROWING ADVANCEMENTS IN LABORATORY TECHNOLOGY, REAGENTS, AND ALTERNATIVE ASSAY METHODOLOGIES TO DRIVE MARKET
• 8.9 ALLERGY DIAGNOSTICS
  • 8.9.1 GROWING FOCUS ON ALLERGY THERAPY AND PREVENTION TO ACCELERATE GROWTH
• 8.10 DRUG MONITORING & TESTING
  • 8.10.1 GROWING IMPLEMENTATION OF DRUGS-OF-ABUSE TESTING TO DRIVE MARKET
• 8.11 OTHER APPLICATIONS

9 IVD REAGENTS MARKET, BY TEST TYPE

• 9.1 INTRODUCTION
• 9.2 LABORATORY TESTS
  • 9.2.1 INCREASING NEED FOR AUTOMATION TO EXPEDITE GROWTH
• 9.3 POINT-OF-CARE TESTS
  • 9.3.1 NEED TO CLOSELY MONITOR PATIENT CONDITIONS TO AUGMENT GROWTH

10 IVD REAGENTS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS & CLINICS
  • 10.2.1 INCREASING SPECIALTY DIAGNOSTIC TESTS TO ACCELERATE GROWTH
• 10.3 CLINICAL LABORATORIES
  • 10.3.1 LARGE REFERENCE LABORATORIES
    • 10.3.1.1 Need for specialized testing capabilities and minimal turnaround time to boost market
  • 10.3.2 SMALL & MEDIUM-SIZED LABORATORIES
    • 10.3.2.1 Growing adoption of automated and semi-automated instruments to support growth
• 10.4 BLOOD BANKS
  • 10.4.1 GROWING NUMBER OF TRAUMA CASES AND AVAILABILITY OF SOPHISTICATED SURGICAL PROCEDURES TO FUEL MARKET
• 10.5 HOME CARE SETTINGS
  • 10.5.1 GROWING PREFERENCE FOR AT-HOME TESTING KITS TO DRIVE MARKET
• 10.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.6.1 INCREASING RESEARCH & DEVELOPMENT EFFORTS TO CONTRIBUTE TO GROWTH
• 10.7 ACADEMIC INSTITUTES
  • 10.7.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS TO FAVOR GROWTH
• 10.8 OTHER END USERS

11 IVD REAGENTS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Established reimbursement framework to drive market
  • 11.2.3 CANADA
    • 11.2.3.1 Rising incidence of chronic and infectious lifestyle diseases to propel market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Increasing investments in clinical diagnostics research to drive market
  • 11.3.3 UK
    • 11.3.3.1 Rising adoption of genome-based testing to promote growth
  • 11.3.4 FRANCE
    • 11.3.4.1 High healthcare expenditure and rising investments in genomic medicine to boost market
  • 11.3.5 ITALY
    • 11.3.5.1 Growing geriatric population and subsequent rise in chronic conditions to support market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Rising adoption of immunoassay reagents to drive market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Rise in social health insurance programs to encourage growth
  • 11.4.3 CHINA
    • 11.4.3.1 Growing focus on preventive care to boost demand
  • 11.4.4 INDIA
    • 11.4.4.1 Rising prevalence of chronic diseases to fuel market
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Rising prevalence of diabetes to stimulate growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Growing establishment of clinical laboratories to boost market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 GROWING FOCUS ON IMMUNOLOGY AND PRENATAL & CANCER TESTING TO DRIVE MARKET
  • 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 11.7 GCC COUNTRIES
  • 11.7.1 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
  • 11.7.2 KINGDOM OF SAUDI ARABIA
    • 11.7.2.1 Rising healthcare expenditure to promote growth
  • 11.7.3 UNITED ARAB EMIRATES
    • 11.7.3.1 Increasing development of advanced healthcare infrastructure to expedite growth
  • 11.7.4 OTHER GCC COUNTRIES

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IVD REAGENTS MARKET, 2021-2023
• 12.3 REVENUE ANALYSIS, 2021-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
• 12.5 COMPANY VALUATION AND FINANCIAL METRICS
• 12.6 BRAND/PRODUCT COMPARISON
• 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.7.1 STARS
  • 12.7.2 EMERGING LEADERS
  • 12.7.3 PERVASIVE PLAYERS
  • 12.7.4 PARTICIPANTS
  • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.7.5.1 Company footprint
    • 12.7.5.2 Technology footprint
    • 12.7.5.3 Application footprint
    • 12.7.5.4 Test type footprint
    • 12.7.5.5 Region footprint
• 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.8.1 PROGRESSIVE COMPANIES
  • 12.8.2 RESPONSIVE COMPANIES
  • 12.8.3 DYNAMIC COMPANIES
  • 12.8.4 STARTING BLOCKS
  • 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 12.8.5.1 Detailed list of key startups/SMEs
    • 12.8.5.2 Competitive benchmarking of key startups/SMEs
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS
  • 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 DANAHER CORPORATION
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Deals
      • 13.1.1.3.2 Expansions
      • 13.1.1.3.3 Other developments
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 ABBOTT
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 SIEMENS HEALTHINEERS AG
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses and competitive threats
  • 13.1.5 THERMO FISHER SCIENTIFIC INC.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
      • 13.1.5.3.2 Expansions
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses and competitive threats
  • 13.1.6 ILLUMINA, INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Deals
  • 13.1.7 BIOMERIEUX
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
  • 13.1.8 BD
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Deals
  • 13.1.9 HOLOGIC, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches and approvals
      • 13.1.9.3.2 Deals
  • 13.1.10 BIO-RAD LABORATORIES, INC.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 SYSMEX CORPORATION
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product launches and approvals
      • 13.1.11.3.2 Deals
      • 13.1.11.3.3 Expansions
  • 13.1.12 QIAGEN N.V.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
  • 13.1.13 AGILENT TECHNOLOGIES, INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
      • 13.1.13.3.2 Expansions
  • 13.1.14 REVVITY
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Deals
      • 13.1.14.3.2 Other developments
  • 13.1.15 DIASORIN S.P.A.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Deals
  • 13.1.16 GRIFOLS, S.A.
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Deals
  • 13.1.17 WERFEN, S.A.
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products offered
    • 13.1.17.3 Recent developments
      • 13.1.17.3.1 Deals
  • 13.1.18 QUIDELORTHO CORPORATION
    • 13.1.18.1 Business overview
    • 13.1.18.2 Products offered
    • 13.1.18.3 Recent developments
      • 13.1.18.3.1 Deals
      • 13.1.18.3.2 Expansions
  • 13.1.19 CHEMBIO DIAGNOSTICS, INC.
    • 13.1.19.1 Business overview
    • 13.1.19.2 Products offered
  • 13.1.20 SURMODICS, INC.
    • 13.1.20.1 Business overview
    • 13.1.20.2 Products offered
  • 13.1.21 MERCK KGAA
    • 13.1.21.1 Business overview
    • 13.1.21.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
  • 13.2.2 CANVAX
  • 13.2.3 PRESTIGE DIAGNOSTICS
  • 13.2.4 ADALTIS S.R.L.
  • 13.2.5 RANDOX LABORATORIES LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

List of Tables

• TABLE 1 IVD REAGENTS MARKET: INCLUSIONS AND EXCLUSIONS
• TABLE 2 IVD REAGENTS MARKET: RISK ASSESSMENT
• TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION, 2022 VS. 2030 VS. 2050
• TABLE 4 RECENT DEVELOPMENTS IN IVD REAGENTS MARKET IN EMERGING ECONOMIES, 2022-2023
• TABLE 5 AVERAGE SELLING PRICE TREND OF KEY PLAYERS FOR TOP 2 APPLICATIONS, 2021-2023 (USD)
• TABLE 6 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY REGION, 2021-2023 (USD)
• TABLE 7 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2021-2023 (USD)
• TABLE 8 IVD REAGENTS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• TABLE 9 IVD REAGENTS MARKET: KEY TECHNOLOGIES
• TABLE 10 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2023 (USD MILLION)
• TABLE 11 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2023 (USD MILLION)
• TABLE 12 IVD REAGENTS MARKET: KEY CONFERENCES AND EVENTS, 2024-2025
• TABLE 13 IVD REAGENTS MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 14 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL FOR IVD REAGENTS
• TABLE 15 US: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
• TABLE 16 CANADA: CLASSIFICATION OF IVD PRODUCTS
• TABLE 17 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
• TABLE 18 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES
• TABLE 19 EUROPE: CLASSIFICATION OF IVD REAGENTS
• TABLE 20 EUROPE: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
• TABLE 21 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
• TABLE 22 JAPAN: CLASSIFICATION OF IVD REAGENTS
• TABLE 23 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
• TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 29 GCC COUNTRIES: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD REAGENTS, BY END USER (%)
• TABLE 31 KEY BUYING CRITERIA FOR IVD REAGENTS, BY END USER
• TABLE 32 IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 33 COMPANIES PROVIDING ANTIBODIES
• TABLE 34 ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 35 ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 36 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 37 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 38 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 39 LATIN AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 40 GCC COUNTRIES: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 41 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 42 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 43 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 44 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 45 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 46 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 47 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 48 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 49 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 50 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 51 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 52 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 53 COMPANIES PROVIDING ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES
• TABLE 54 ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 55 NORTH AMERICA: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 56 EUROPE: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 57 ASIA PACIFIC: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 58 LATIN AMERICA: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 59 GCC COUNTRIES: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 60 COMPANIES PROVIDING OLIGONUCLEOTIDES
• TABLE 61 OLIGONUCLEOTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 63 EUROPE: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 66 GCC COUNTRIES: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 67 COMPANIES PROVIDING NUCLEIC ACID PROBES
• TABLE 68 NUCLEIC ACID PROBES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 69 NORTH AMERICA: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 70 EUROPE: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 71 ASIA PACIFIC: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 72 LATIN AMERICA: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 73 GCC COUNTRIES: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 74 COMPANIES PROVIDING OTHER IVD REAGENTS
• TABLE 75 OTHER IVD REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 76 NORTH AMERICA: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 77 EUROPE: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 78 ASIA PACIFIC: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 79 LATIN AMERICA: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 80 GCC COUNTRIES: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 81 IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 82 IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 83 NORTH AMERICA: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 84 EUROPE: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 85 ASIA PACIFIC: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 86 LATIN AMERICA: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 87 GCC COUNTRIES: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 88 IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 89 NORTH AMERICA: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 90 EUROPE: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 91 ASIA PACIFIC: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 92 LATIN AMERICA: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 93 GCC COUNTRIES: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 94 IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 95 NORTH AMERICA: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 96 EUROPE: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 97 ASIA PACIFIC: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 98 LATIN AMERICA: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 99 GCC COUNTRIES: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 100 IVD REAGENTS MARKET FOR HEMATOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 101 NORTH AMERICA: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 102 EUROPE: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 103 ASIA PACIFIC: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 104 LATIN AMERICA: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 105 GCC COUNTRIES: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 106 IVD REAGENTS MARKET FOR MICROBIOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 107 NORTH AMERICA: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 108 EUROPE: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 109 ASIA PACIFIC: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 110 LATIN AMERICA: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 111 GCC COUNTRIES: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 112 IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 113 NORTH AMERICA: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 114 EUROPE: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 115 ASIA PACIFIC: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 116 LATIN AMERICA: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 117 GCC COUNTRIES: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 118 IVD REAGENTS MARKET FOR URINALYSIS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 119 NORTH AMERICA: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 120 EUROPE: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 121 ASIA PACIFIC: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 122 LATIN AMERICA: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 123 GCC COUNTRIES: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 124 IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 125 NORTH AMERICA: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 126 EUROPE: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 127 ASIA PACIFIC: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 128 LATIN AMERICA: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 129 GCC COUNTRIES: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 130 IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 131 NORTH AMERICA: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 132 EUROPE: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 133 ASIA PACIFIC: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 134 LATIN AMERICA: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 135 GCC COUNTRIES: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 136 IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 137 IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 138 NORTH AMERICA: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 139 EUROPE: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 140 ASIA PACIFIC: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 141 LATIN AMERICA: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 142 GCC COUNTRIES: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 143 ESTIMATED NUMBER OF NEW CASES OF CANCER FOR 0-85+ YEARS OF AGE, 2022 VS. 2030
• TABLE 144 IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 145 NORTH AMERICA: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 146 EUROPE: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 147 ASIA PACIFIC: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 148 LATIN AMERICA: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 149 GCC COUNTRIES: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 150 IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 151 NORTH AMERICA: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 152 EUROPE: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 153 ASIA PACIFIC: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 154 LATIN AMERICA: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 155 GCC COUNTRIES: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 156 IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 157 NORTH AMERICA: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 158 EUROPE: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 159 ASIA PACIFIC: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 160 LATIN AMERICA: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 161 GCC COUNTRIES: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 162 IVD REAGENTS MARKET FOR BLOOD SCREENING, BY REGION, 2022-2029 (USD MILLION)
• TABLE 163 NORTH AMERICA: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 164 EUROPE: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 165 ASIA PACIFIC: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 166 LATIN AMERICA: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 167 GCC COUNTRIES: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 168 IVD REAGENTS MARKET FOR GENETIC TESTING, BY REGION, 2022-2029 (USD MILLION)
• TABLE 169 NORTH AMERICA: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 170 EUROPE: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 171 ASIA PACIFIC: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 172 LATIN AMERICA: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 173 GCC COUNTRIES: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 174 IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 175 NORTH AMERICA: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 176 EUROPE: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 177 ASIA PACIFIC: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 178 LATIN AMERICA: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 179 GCC COUNTRIES: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 180 IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 181 NORTH AMERICA: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 182 EUROPE: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 183 ASIA PACIFIC: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 184 LATIN AMERICA: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 185 GCC COUNTRIES: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 186 KEY PRODUCTS FOR DRUG MONITORING
• TABLE 187 IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2022-2029 (USD MILLION)
• TABLE 188 NORTH AMERICA: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 189 EUROPE: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 190 ASIA PACIFIC: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 191 LATIN AMERICA: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 192 GCC COUNTRIES: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 193 IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 194 NORTH AMERICA: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 195 EUROPE: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 196 ASIA PACIFIC: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 197 LATIN AMERICA: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 198 GCC COUNTRIES: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 199 IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 200 IVD REAGENTS MARKET FOR LABORATORY TESTS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 201 NORTH AMERICA: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 202 EUROPE: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 203 ASIA PACIFIC: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 204 LATIN AMERICA: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 205 GCC COUNTRIES: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 206 IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 207 NORTH AMERICA: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 208 EUROPE: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 209 ASIA PACIFIC: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 210 LATIN AMERICA: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 211 GCC COUNTRIES: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 212 IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 213 IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 214 NORTH AMERICA: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 215 EUROPE: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 216 ASIA PACIFIC: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 217 LATIN AMERICA: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 218 GCC COUNTRIES: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 219 IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 220 IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 221 NORTH AMERICA: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 222 EUROPE: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 223 ASIA PACIFIC: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 224 LATIN AMERICA: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 225 GCC COUNTRIES: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 226 IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 227 NORTH AMERICA: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 228 EUROPE: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 229 ASIA PACIFIC: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 230 LATIN AMERICA: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 231 GCC COUNTRIES: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 232 IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 233 NORTH AMERICA: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 234 EUROPE: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 235 ASIA PACIFIC: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 236 LATIN AMERICA: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 237 GCC COUNTRIES: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 238 IVD REAGENTS MARKET FOR BLOOD BANKS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 239 NORTH AMERICA: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 240 EUROPE: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 241 ASIA PACIFIC: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 242 LATIN AMERICA: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 243 GCC COUNTRIES: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 244 IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 245 NORTH AMERICA: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 246 EUROPE: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 247 ASIA PACIFIC: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 248 LATIN AMERICA: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 249 GCC COUNTRIES: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 250 IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 251 NORTH AMERICA: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 252 EUROPE: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 253 ASIA PACIFIC: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 254 LATIN AMERICA: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 255 GCC COUNTRIES: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 256 IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 257 NORTH AMERICA: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 258 EUROPE: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 259 ASIA PACIFIC: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 260 LATIN AMERICA: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 261 GCC COUNTRIES: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 262 IVD REAGENTS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 263 NORTH AMERICA: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 264 EUROPE: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 265 ASIA PACIFIC: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 266 LATIN AMERICA: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 267 GCC COUNTRIES: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 268 IVD REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 269 KEY IVD REAGENTS PROVIDED BY MAJOR PLAYERS IN NORTH AMERICA
• TABLE 270 NORTH AMERICA: MACROECONOMIC INDICATORS
• TABLE 271 NORTH AMERICA: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 272 NORTH AMERICA: IVD TESTS CONDUCTED, BY COUNTRY, 2022-2029 (BILLION UNIT)
• TABLE 273 NORTH AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 274 NORTH AMERICA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 275 NORTH AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 276 NORTH AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 277 NORTH AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 278 NORTH AMERICA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 279 NORTH AMERICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 280 US: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 281 US: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 282 US: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 283 US: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 284 US: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 285 US: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 286 US: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 287 CANADA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 288 CANADA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 289 CANADA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 290 CANADA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 291 CANADA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 292 CANADA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 293 CANADA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 294 KEY IVD REAGENTS PROVIDED BY MAJOR PLAYERS IN EUROPE
• TABLE 295 EUROPE: MACROECONOMIC INDICATORS
• TABLE 296 EUROPE: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 297 EUROPE: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 298 EUROPE: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 299 EUROPE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 300 EUROPE: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 301 EUROPE: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 302 EUROPE: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 303 EUROPE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 304 GERMANY: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 305 GERMANY: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 306 GERMANY: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 307 GERMANY: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 308 GERMANY: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 309 GERMANY: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 310 GERMANY: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 311 UK: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 312 UK: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 313 UK: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 314 UK: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 315 UK: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 316 UK: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 317 UK: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 318 FRANCE: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 319 FRANCE: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 320 FRANCE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 321 FRANCE: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 322 FRANCE: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 323 FRANCE: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 324 FRANCE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 325 ITALY: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 326 ITALY: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 327 ITALY: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 328 ITALY: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 329 ITALY: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 330 ITALY: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 331 ITALY: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 332 SPAIN: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 333 SPAIN: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 334 SPAIN: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 335 SPAIN: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 336 SPAIN: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 337 SPAIN: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 338 SPAIN: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 339 REST OF EUROPE: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 340 REST OF EUROPE: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 341 REST OF EUROPE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 342 REST OF EUROPE: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 343 REST OF EUROPE: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 344 REST OF EUROPE: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 345 REST OF EUROPE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 346 ASIA PACIFIC: MACROECONOMIC INDICATORS
• TABLE 347 ASIA PACIFIC: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 348 ASIA PACIFIC: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 349 ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 350 ASIA PACIFIC: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 351 ASIA PACIFIC: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 352 ASIA PACIFIC: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 353 ASIA PACIFIC: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 354 ASIA PACIFIC: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 355 JAPAN: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 356 JAPAN: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 357 JAPAN: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 358 JAPAN: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 359 JAPAN: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 360 JAPAN: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 361 JAPAN: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 362 CHINA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 363 CHINA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 364 CHINA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 365 CHINA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 366 CHINA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 367 CHINA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 368 CHINA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 369 INDIA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 370 INDIA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 371 INDIA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 372 INDIA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 373 INDIA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 374 INDIA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 375 INDIA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 376 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 377 REST OF ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 378 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 379 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 380 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 381 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 382 REST OF ASIA PACIFIC: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 383 LATIN AMERICA: MACROECONOMIC INDICATORS
• TABLE 384 LATIN AMERICA: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 385 LATIN AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 386 LATIN AMERICA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 387 LATIN AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 388 LATIN AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 389 LATIN AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 390 LATIN AMERICA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 391 LATIN AMERICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 392 BRAZIL: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 393 BRAZIL: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 394 BRAZIL: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 395 BRAZIL: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 396 BRAZIL: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 397 BRAZIL: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 398 BRAZIL: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 399 MEXICO: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 400 MEXICO: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 401 MEXICO: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 402 MEXICO: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 403 MEXICO: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 404 MEXICO: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 405 MEXICO: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 406 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 407 REST OF LATIN AMERICA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 408 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 409 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 410 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 411 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 412 REST OF LATIN AMERICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 413 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
• TABLE 414 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 415 MIDDLE EAST & AFRICA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 416 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 417 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 418 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 419 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 420 MIDDLE EAST & AFRICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 421 GCC COUNTRIES: MACROECONOMIC INDICATORS
• TABLE 422 GCC COUNTRIES: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 423 GCC COUNTRIES: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 424 GCC COUNTRIES: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 425 GCC COUNTRIES: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 426 GCC COUNTRIES: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 427 GCC COUNTRIES: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 428 GCC COUNTRIES: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 429 GCC COUNTRIES: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 430 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 431 KINGDOM OF SAUDI ARABIA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 432 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 433 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 434 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 435 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 436 KINGDOM OF SAUDI ARABIA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 437 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 438 UNITED ARAB EMIRATES: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 439 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 440 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 441 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 442 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 443 UNITED ARAB EMIRATES: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 444 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 445 OTHER GCC COUNTRIES: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 446 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 447 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 448 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
• TABLE 449 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 450 OTHER GCC COUNTRIES: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 451 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IVD REAGENTS MARKET, 2021-2023
• TABLE 452 IVD REAGENTS MARKET: DEGREE OF COMPETITION
• TABLE 453 IVD REAGENTS MARKET: TECHNOLOGY FOOTPRINT
• TABLE 454 IVD REAGENTS MARKET: APPLICATION FOOTPRINT
• TABLE 455 IVD REAGENTS MARKET: TEST TYPE FOOTPRINT
• TABLE 456 IVD REAGENTS MARKET: REGION FOOTPRINT
• TABLE 457 IVD REAGENTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 458 IVD REAGENTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
• TABLE 459 IVD REAGENTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 460 IVD REAGENTS MARKET: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 461 IVD REAGENTS MARKET: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
• TABLE 462 IVD REAGENTS MARKET: OTHER DEVELOPMENTS, JANUARY 2021-SEPTEMBER 2024
• TABLE 463 DANAHER CORPORATION: COMPANY OVERVIEW
• TABLE 464 DANAHER CORPORATION: PRODUCTS OFFERED
• TABLE 465 DANAHER CORPORATION: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 466 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
• TABLE 467 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021-SEPTEMBER 2024
• TABLE 468 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• TABLE 469 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
• TABLE 470 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 471 ABBOTT: COMPANY OVERVIEW
• TABLE 472 ABBOTT: PRODUCTS OFFERED
• TABLE 473 ABBOTT: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 474 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
• TABLE 475 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
• TABLE 476 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 477 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• TABLE 478 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
• TABLE 479 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 480 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
• TABLE 481 ILLUMINA, INC.: COMPANY OVERVIEW
• TABLE 482 ILLUMINA, INC.: PRODUCTS OFFERED
• TABLE 483 ILLUMINA, INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 484 BIOMERIEUX: COMPANY OVERVIEW
• TABLE 485 BIOMERIEUX: PRODUCTS OFFERED
• TABLE 486 BIOMERIEUX: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 487 BD: COMPANY OVERVIEW
• TABLE 488 BD: PRODUCTS OFFERED
• TABLE 489 BD: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 490 HOLOGIC, INC.: COMPANY OVERVIEW
• TABLE 491 HOLOGIC, INC.: PRODUCTS OFFERED
• TABLE 492 HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 493 HOLOGIC, INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 494 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
• TABLE 495 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
• TABLE 496 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 497 SYSMEX CORPORATION: COMPANY OVERVIEW
• TABLE 498 SYSMEX CORPORATION: PRODUCTS OFFERED
• TABLE 499 SYSMEX CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 500 SYSMEX CORPORATION: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 501 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
• TABLE 502 QIAGEN N.V.: COMPANY OVERVIEW
• TABLE 503 QIAGEN N.V.: PRODUCTS OFFERED
• TABLE 504 QIAGEN N.V.: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 505 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
• TABLE 506 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
• TABLE 507 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 508 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
• TABLE 509 REVVITY: COMPANY OVERVIEW
• TABLE 510 REVVITY: PRODUCTS OFFERED
• TABLE 511 REVVITY: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 512 REVVITY: OTHER DEVELOPMENTS, JANUARY 2021-SEPTEMBER 2024
• TABLE 513 DIASORIN S.P.A.: COMPANY OVERVIEW
• TABLE 514 DIASORIN S.P.A.: PRODUCTS OFFERED
• TABLE 515 DIASORIN S.P.A.: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 516 GRIFOLS S.A.: COMPANY OVERVIEW
• TABLE 517 GRIFOLS S.A.: PRODUCTS OFFERED
• TABLE 518 GRIFOLS S.A.: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 519 WERFEN, S.A.: COMPANY OVERVIEW
• TABLE 520 WERFEN, S.A.: PRODUCTS OFFERED
• TABLE 521 WERFEN, S.A.: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 522 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
• TABLE 523 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
• TABLE 524 QUIDELORTHO CORPORATION: DEALS, JANUARY 2021-SEPTEMBER 2024
• TABLE 525 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
• TABLE 526 CHEMBIO DIAGNOSTICS, INC.: COMPANY OVERVIEW
• TABLE 527 CHEMBIO DIAGNOSTICS, INC.: PRODUCTS OFFERED
• TABLE 528 SURMODICS, INC.: COMPANY OVERVIEW
• TABLE 529 SURMODICS, INC.: PRODUCTS OFFERED
• TABLE 530 MERCK KGAA: COMPANY OVERVIEW
• TABLE 531 MERCK KGAA: PRODUCTS OFFERED
• TABLE 532 MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.: COMPANY OVERVIEW
• TABLE 533 CANVAX: COMPANY OVERVIEW
• TABLE 534 PRESTIGE DIAGNOSTICS: COMPANY OVERVIEW
• TABLE 535 ADALTIS S.R.L.: COMPANY OVERVIEW
• TABLE 536 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW

List of Figures

• FIGURE 1 IVD REAGENTS MARKET SEGMENTATION AND REGIONAL SCOPE
• FIGURE 2 IVD REAGENTS MARKET: RESEARCH DESIGN
• FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
• FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 6 IVD REAGENTS MARKET: TOP-DOWN APPROACH
• FIGURE 7 DATA TRIANGULATION METHODOLOGY
• FIGURE 8 IVD REAGENTS MARKET, BY TYPE, 2024-2029 (USD MILLION)
• FIGURE 9 IVD REAGENTS MARKET, BY TECHNOLOGY, 2024-2029 (USD MILLION)
• FIGURE 10 IVD REAGENTS MARKET, BY APPLICATION, 2024-2029 (USD MILLION)
• FIGURE 11 IVD REAGENTS MARKET, BY TEST TYPE, 2024-2029 (USD MILLION)
• FIGURE 12 IVD REAGENTS MARKET, BY END USER, 2024-2029 (USD MILLION)
• FIGURE 13 IVD REAGENTS MARKET, BY REGION, 2024-2029 (USD MILLION)
• FIGURE 14 INCREASING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
• FIGURE 15 CHINA TO LEAD MARKET DURING FORECAST PERIOD
• FIGURE 16 US AND LABORATORY TESTS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN IVD REAGENTS MARKET IN 2023
• FIGURE 17 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
• FIGURE 18 IVD REAGENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 19 CRITICAL IMPACT AREAS OF IVD REAGENTS
• FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 21 IVD REAGENTS MARKET: VALUE CHAIN ANALYSIS
• FIGURE 22 IVD REAGENTS MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 23 IVD REAGENTS MARKET: ECOSYSTEM ANALYSIS
• FIGURE 24 IVD REAGENTS MARKET: INVESTMENT AND FUNDING SCENARIO, 2019-2024
• FIGURE 25 IVD REAGENTS MARKET: PATENT ANALYSIS, JANUARY 2014-MARCH 2024
• FIGURE 26 IVD REAGENTS MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD REAGENTS, BY END USER
• FIGURE 28 KEY BUYING CRITERIA FOR IVD REAGENTS, BY END USER
• FIGURE 29 NORTH AMERICA: IVD REAGENTS MARKET SNAPSHOT
• FIGURE 30 ASIA PACIFIC: IVD REAGENTS MARKET SNAPSHOT
• FIGURE 31 IVD REAGENTS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD MILLION)
• FIGURE 32 IVD REAGENTS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
• FIGURE 33 FINANCIAL METRICS
• FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, (2021-2023)
• FIGURE 35 IVD REAGENTS MARKET: BRAND/PRODUCT COMPARISON
• FIGURE 36 IVD REAGENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 37 IVD REAGENTS MARKET: COMPANY FOOTPRINT
• FIGURE 38 IVD REAGENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
• FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
• FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2023)
• FIGURE 42 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
• FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
• FIGURE 44 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 45 BIOMERIEUX: COMPANY SNAPSHOT (2023)
• FIGURE 46 BD: COMPANY SNAPSHOT (2023)
• FIGURE 47 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 48 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 49 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
• FIGURE 50 QIAGEN N.V.: COMPANY SNAPSHOT (2023)
• FIGURE 51 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 52 REVVITY: COMPANY SNAPSHOT (2023)
• FIGURE 53 DIASORIN S.P.A.: COMPANY SNAPSHOT (2023)
• FIGURE 54 GRIFOLS S.A.: COMPANY SNAPSHOT (2023)
• FIGURE 55 WERFEN, S.A.: COMPANY SNAPSHOT (2023)
• FIGURE 56 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2023)
• FIGURE 57 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
• FIGURE 58 SURMODICS, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 59 MERCK KGAA: COMPANY SNAPSHOT (2023)